Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Digestive complications in AML induction: Spotlight on neutropenic enterocolitis

Ornesta Bezhani, Raphaël Pichois, Magalie Joris, Lydia Montes, Hélène Kemp, Amandine Charbonnier, Sylvain Chantepie, Emilie Lemasle, Jean Pierre Marolleau, Delphine Lebon

Blood (2025) 146 (Supplement 1): 8201.

https://doi.org/10.1182/blood-2025-8201

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Blood (2025) 146 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2025-3594

Published: 2025

Journal Articles

Only young age and genetics retain prognostic value for 2-year relapse-free survival in AML

Wissam Mahrez, Céline Berthon, Laurene Fenwarth, Carine Hauspie, Nicolas Duployez, Claude Preudhomme, Magalie Joris, Jean Pierre Marolleau, Delphine Lebon

Blood (2025) 146 (Supplement 1): 3382.

https://doi.org/10.1182/blood-2025-3382

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Blood (2025) 146 (Supplement 1): 5377.

https://doi.org/10.1182/blood-2025-5377

Published: 2025

Journal Articles

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

Blood (2025) 146 (Supplement 1): 368.

https://doi.org/10.1182/blood-2025-368

Published: 2025

Journal Articles

PIEZO1 activation controls erythropoiesis through calpain-dependent degradation of HSP70

Alexandre Willaume, Jessica Platon, Hakim Ouled-Haddou, Anaelle Lavillette, Emilie-Fleur Gautier, Virginie Salnot, Veronique Picard, Christilla Bachelot-Loza, Pascale Gaussem, Zoubida Karim, Jean Pierre Marolleau, Alexis Caulier, Loic Garcon

Blood (2025) 146 (Supplement 1): 609.

https://doi.org/10.1182/blood-2025-609

Published: 2025

Journal Articles

Pharmacological inhibition of polrmt mimicking polrmt rare variants associated with sideroblastic anemia, strongly inhibits proliferation and differentiation of human erythroblasts

Ophélie Evrard, Cécile Deleschaux, Sophie Lefevre, Hakim Ouled-Haddou, Platon Jessica, Valérie Li Thiao Te, Catherine Paillard, Jean Pierre Marolleau, Mariano Ostuni, Kannengiesser Caroline, Loic Garcon

Blood (2025) 146 (Supplement 1): 4658.

https://doi.org/10.1182/blood-2025-4658

Published: 2025

Journal Articles

Long-term follow-up of the STOPAGO study

Blood (2025) 145 (2): 244–247.

https://doi.org/10.1182/blood.2024025707

Published: 2025

Includes: Supplemental data

Journal Articles

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Jill Corre, Jérôme Lambert, Arthur Bobin, Salomon Manier, Aurore Perrot, Lionel Karlin, Murielle Roussel, Noemie Bigot, Omar Benbrahim, Olivier Thierry Allangba, Philippe Rey, Veronique Dorvaux, Marguerite Vignon, Virginie Roland, Reda Garidi, Jean-Noel Bastie, Marie-Lorraine Chrétien, Sophie Godet, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Kamel Laribi, Claire Dingremont, Christophe Roul, Valentine Richez, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Jean Pierre Marolleau, Pascal Godmer, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Helene Gardeney, Margaret Macro, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj Merzoug, Cyrille Touzeau, Mohamad Mohty, Aurelie Gontier, Amine Kasmi, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Cyrille Hulin, Xavier Leleu

Blood (2024) 144 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2024-210345

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Blood (2024) 144 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2024-201269

Published: 2024

Journal Articles

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

Blood (2024) 144 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2024-204593

Published: 2024

Journal Articles

The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy

Hélène Kemp, Laurène Fenwarth, Delphine Lebon, Nicolas Duployez, Etienne Paubelle, Magalie Joris, Amandine Charbonnier, Lydia Montes, Claude Preudhomme, Christophe Tribouilloy, Jean Pierre Marolleau, Pierre Morel

Blood (2023) 142 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2023-190177

Published: 2023

Journal Articles

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Blood (2023) 142 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2023-174446

Published: 2023

Journal Articles

Prognostic Value and Functional Consequences of Calcium Signalling in Acute Myeloid Leukaemia

Stefan Djordjevic, Delphine Lebon, Raphael Itzykson, Hakim Ouled-Haddou, Guillaume Jedraszak, Juliette Harbonnier, Louison Collet, Etienne Paubelle, Nicolas Duployez, Jean Pierre Marolleau, Loïc Garçon, Thomas Boyer

Blood (2023) 142 (Supplement 1): 5678.

https://doi.org/10.1182/blood-2023-179276

Published: 2023

Journal Articles

Impact of Residence in an Agricultural Zone on AML Characteristics

Vincent Marmouset, Berengere Gruson, Veronique Harrivel, Céline Berthon, Nicolas Duployez, Claude Preudhomme, Jean Pierre Marolleau, Pierre Morel, Carine Hauspie, Stéphane Morisset, Delphine Lebon

Blood (2023) 142 (Supplement 1): 2842.

https://doi.org/10.1182/blood-2023-173171

Published: 2023

Journal Articles

Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study

Blood (2023) 141 (23): 2867–2877.

https://doi.org/10.1182/blood.2022018665

Published: 2023

Includes: Supplemental data

Journal Articles

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Blood (2023) 141 (11): 1308–1315.

https://doi.org/10.1182/blood.2022017863

Published: 2023

Includes: Supplemental data

Journal Articles

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Laura Simon, Alexis Caulier, Celine Berthon, Thomas Boyer, Véronique Harrivel, Magalie Joris, Amandine Charbonnier, Etienne Paubelle, Isabelle Leduc, Nicolas Duployez, Christophe Roumier, Claude Preudhomme, Stéphane Morisset, Jean-Pierre Marolleau, Delphine Lebon

Blood (2022) 140 (Supplement 1): 3225–3226.

https://doi.org/10.1182/blood-2022-164840

Published: 2022

Journal Articles

In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

Blood (2022) 140 (Supplement 1): 112–114.

https://doi.org/10.1182/blood-2022-157903

Published: 2022

Journal Articles

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Blood (2022) 139 (17): 2666–2672.

https://doi.org/10.1182/blood.2021014968

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Digestive complications in AML induction: Spotlight on neutropenic enterocolitis

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Only young age and genetics retain prognostic value for 2-year relapse-free survival in AML

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

PIEZO1 activation controls erythropoiesis through calpain-dependent degradation of HSP70

Pharmacological inhibition of polrmt mimicking polrmt rare variants associated with sideroblastic anemia, strongly inhibits proliferation and differentiation of human erythroblasts

Long-term follow-up of the STOPAGO study

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab

The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Prognostic Value and Functional Consequences of Calcium Signalling in Acute Myeloid Leukaemia

Impact of Residence in an Agricultural Zone on AML Characteristics

Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only